AstraZeneca PLC (LSE:AZN)
£ 122.46 -0.72 (-0.58%) Market Cap: 189.84 Bil Enterprise Value: 210.96 Bil PE Ratio: 37.91 PB Ratio: 6.44 GF Score: 85/100

AstraZeneca PLC Investor Conference Call: Farxiga's DAPA-CKD Trial at ESC 2020 Transcript

Aug 30, 2020 / NTS GMT
Pascal Soriot
AstraZeneca PLC - CEO & Executive Director

Good afternoon, everybody. Thank you so much for joining us for this very exciting discussion today on a very, very important set of data that we have just presented at the ESC.

So if we move to the Slide 3, this shows you the agenda for today. I will give you a short introduction, and then you will hear Professor Hiddo Heerspink present the data, and then we'll move to a Q&A.

So if we move to Slide 4, just want to say that the presenters for today will be Hiddo, of course; David Wheeler from University College London; Ruud Dobber, our EVP for our BioPharmaceuticals Business Unit; Mene Pangalos, the EVP for BioPharma R&D; and Elisabeth Björk, who is with the SVP for CVRM. They are available for the Q&A, and we may also call on other team members who are with us today in case we have additional questions.

We move to Slide 5. This slide actually shows you the, I would think, the incredible journey that Farxiga has been on from the early days when basically everybody saw this molecule as a simple diabetes drug

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot